Roche is stepping into the MASH/NASH race. The company will acquire 89bio (ETNB)  for $14.50/share in cash  (~$2.4B equity value). On top of that, shareholders get a CVR worth up to $6.00/share , bringing the total potential deal value to $3.5B .

Roche is stepping into the MASH/NASH race. The company will acquire 89bio (ETNB)  for $14.50/share in cash  (~$2.4B equity value). On top of that, shareholders get a CVR worth up to $6.00/share , bringing the total potential deal value to $3.5B .   The Asset The prize is pegozafermin (pego) , 89bio’s lead program for MASH/NASH. Pego is a glycoPEGylated FGF21 analog . Designed to drive weight loss, reduce liver fat, and improve fibrosis.   Deal Terms Cash upfront:  $14.50/shar

$XBI $74.06 | -3.57% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates #NVAX -5.1% Novavax to...

$XBI $74.06 | -3.57% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates #NVAX -5.1% Novavax to...